High Dose Hypofractionated Proton Beam Therapy is a Safe and Feasible Treatment for Central Lung Cancer

Overview

Journal Radiol Oncol

Publisher Sciendo

Specialties Oncology
Radiology

Date 2017 Sep 30

PMID 28959169

Citations 3

Authors

Takashi Ono

Tomonori Yabuuchi

Tatsuya Nakamura

Kanako Kimura

Yusuke Azami

Katsumi Hirose

Motohisa Suzuki

Hitoshi Wada

Yasuhiro Kikuchi

Kenji Nemoto

Affiliations

Soon will be listed here.

Abstract

Background: There have been few reports about high total dose hypofractionated proton beam therapy for central lung cancer. The aim of this study was to examine retrospectively the safety and efficacy of high total dose hypofractionated proton beam therapy for central lung cancer.

Patients And Methods: Patients treated by proton beam therapy for central lung cancer located less than 2 cm from the trachea, mainstem bronchus, or lobe bronchus were included in this study. All patients received 80 Gy of relative biological dose effectiveness (RBE) in 25 fractions with proton beam therapy over 5 weeks between January 2009 and February 2015. The toxicities were evaluated using the Radiation Therapy Oncology Group and European Organization for Research and Treatment of Cancer criteria.

Results: Twenty patients, including 14 clinically inoperable patients (70%), received proton beam therapy for central lung cancer. The median patient age was 75 years (range: 63-90 years), the median follow up time was 27.5 months (range: 12-72 months), and the median tumor diameter was 39.5 mm (range: 24-81 mm). All patients were followed for at least 20 months or until death. The 2-year overall survival rate was 73.8% (100% in operable patients, and 62.5% in inoperable patients), and the 2-year local control rate was 78.5%. There was no Grade 3 or higher toxicities, including bronchial stricture, obstruction, and fistula.

Conclusions: The present study suggests that a high total dose hypofractionated proton beam therapy for central lung cancer was safe and feasible.

Citing Articles

Proton Beam Therapy as a Curative Treatment for a Young Case of Unresectable Tracheal Adenoid Cystic Carcinoma.

Kinoshita T, Ishii H, Sakazaki Y, Azuma K, Sasaki J, Tokito T Intern Med. 2023; 62(19):2877-2881.

PMID: 36792199 PMC: 10602834. DOI: 10.2169/internalmedicine.0574-22.

Normofractionated and moderately hypofractionated proton therapy: comparison of acute toxicity and early quality of life outcomes.

Pelak M, Flechl B, Hug E, Galalae R, Konrath L, Gora J Front Oncol. 2022; 12:962697.

PMID: 36052240 PMC: 9425455. DOI: 10.3389/fonc.2022.962697.

The Role of Hypofractionation in Proton Therapy.

Santos A, Penfold S, Gorayski P, Le H Cancers (Basel). 2022; 14(9).

PMID: 35565400 PMC: 9104796. DOI: 10.3390/cancers14092271.

References

Chang J, Senan S, Paul M, Mehran R, Louie A, Balter P . Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015; 16(6):630-7. PMC: 4489408. DOI: 10.1016/S1470-2045(15)70168-3. View

Mangona V, Aneese A, Marina O, Hymas R, Ionascu D, Robertson J . Toxicity after central versus peripheral lung stereotactic body radiation therapy: a propensity score matched-pair analysis. Int J Radiat Oncol Biol Phys. 2014; 91(1):124-32. DOI: 10.1016/j.ijrobp.2014.08.345. View

Young H, Baum R, Cremerius U, Herholz K, Hoekstra O, Lammertsma A . Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer. 2000; 35(13):1773-82. DOI: 10.1016/s0959-8049(99)00229-4. View

Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T . Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys. 2005; 63(5):1427-31. DOI: 10.1016/j.ijrobp.2005.05.034. View

Matsuo Y, Shibuya K, Nakamura M, Narabayashi M, Sakanaka K, Ueki N . Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer. Int J Radiat Oncol Biol Phys. 2012; 83(4):e545-9. DOI: 10.1016/j.ijrobp.2012.01.018. View

Register S, Zhang X, Mohan R, Chang J . Proton stereotactic body radiation therapy for clinically challenging cases of centrally and superiorly located stage I non-small-cell lung cancer. Int J Radiat Oncol Biol Phys. 2010; 80(4):1015-22. PMC: 2952351. DOI: 10.1016/j.ijrobp.2010.03.012. View

Fitzmaurice C, Dicker D, Pain A, Hamavid H, Moradi-Lakeh M, MacIntyre M . The Global Burden of Cancer 2013. JAMA Oncol. 2015; 1(4):505-27. PMC: 4500822. DOI: 10.1001/jamaoncol.2015.0735. View

Li Q, Swanick C, Allen P, Gomez D, Welsh J, Liao Z . Stereotactic ablative radiotherapy (SABR) using 70 Gy in 10 fractions for non-small cell lung cancer: exploration of clinical indications. Radiother Oncol. 2014; 112(2):256-61. DOI: 10.1016/j.radonc.2014.07.010. View

Suit H, Goldberg S, Niemierko A, Trofimov A, Adams J, Paganetti H . Proton beams to replace photon beams in radical dose treatments. Acta Oncol. 2004; 42(8):800-8. DOI: 10.1080/02841860310017676. View

10.

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

11.

Nakayama H, Sugahara S, Tokita M, Satoh H, Tsuboi K, Ishikawa S . Proton beam therapy for patients with medically inoperable stage I non-small-cell lung cancer at the university of tsukuba. Int J Radiat Oncol Biol Phys. 2010; 78(2):467-71. DOI: 10.1016/j.ijrobp.2009.07.1707. View

12.

Lischalk J, Malik R, Collins S, Collins B, Matus I, Anderson E . Stereotactic body radiotherapy (SBRT) for high-risk central pulmonary metastases. Radiat Oncol. 2016; 11:28. PMC: 4769488. DOI: 10.1186/s13014-016-0608-8. View

13.

Song S, Choi W, Shin S, Lee S, Ahn S, Kim J . Fractionated stereotactic body radiation therapy for medically inoperable stage I lung cancer adjacent to central large bronchus. Lung Cancer. 2009; 66(1):89-93. DOI: 10.1016/j.lungcan.2008.12.016. View

14.

Tekatli H, Senan S, Dahele M, Slotman B, Verbakel W . Stereotactic ablative radiotherapy (SABR) for central lung tumors: Plan quality and long-term clinical outcomes. Radiother Oncol. 2015; 117(1):64-70. DOI: 10.1016/j.radonc.2015.09.028. View

15.

Chang J, Komaki R, Wen H, de Gracia B, Bluett J, McAleer M . Toxicity and patterns of failure of adaptive/ablative proton therapy for early-stage, medically inoperable non-small cell lung cancer. Int J Radiat Oncol Biol Phys. 2011; 80(5):1350-7. PMC: 3117089. DOI: 10.1016/j.ijrobp.2010.04.049. View

16.

Nagata Y, Hiraoka M, Shibata T, Onishi H, Kokubo M, Karasawa K . Prospective Trial of Stereotactic Body Radiation Therapy for Both Operable and Inoperable T1N0M0 Non-Small Cell Lung Cancer: Japan Clinical Oncology Group Study JCOG0403. Int J Radiat Oncol Biol Phys. 2015; 93(5):989-96. DOI: 10.1016/j.ijrobp.2015.07.2278. View

17.

Bush D, Cheek G, Zaheer S, Wallen J, Mirshahidi H, Katerelos A . High-dose hypofractionated proton beam radiation therapy is safe and effective for central and peripheral early-stage non-small cell lung cancer: results of a 12-year experience at Loma Linda University Medical Center. Int J Radiat Oncol Biol Phys. 2013; 86(5):964-8. DOI: 10.1016/j.ijrobp.2013.05.002. View

18.

Torre L, Bray F, Siegel R, Ferlay J, Lortet-Tieulent J, Jemal A . Global cancer statistics, 2012. CA Cancer J Clin. 2015; 65(2):87-108. DOI: 10.3322/caac.21262. View

19.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

20.

Modh A, Rimner A, Williams E, Foster A, Shah M, Shi W . Local control and toxicity in a large cohort of central lung tumors treated with stereotactic body radiation therapy. Int J Radiat Oncol Biol Phys. 2014; 90(5):1168-76. PMC: 4276458. DOI: 10.1016/j.ijrobp.2014.08.008. View